Roche’s immunotherapy combo receives FDA priority review – BioPharma-Reporter.com
BioPharma-Reporter.com |
Roche's immunotherapy combo receives FDA priority review
BioPharma-Reporter.com Roche's immunotherapy combination has received priority review after Phase III trial results showed potential to provide significant survival benefit in the initial treatment of NSCLC. The US Food and Drug Administration (FDA) has granted Roche … |
